Richard Mulligan net worth and biography

Richard Mulligan Biography and Net Worth

Director of Sana Biotechnology

Richard Mulligan, Ph.D. has served as a member of our Board since November 2018 and as Vice-Chairman since April 2020. Previously, Dr. Mulligan served as a consultant to Sana from November 2018 until joining Sana as an employee in April 2018, where he served in various roles, most recently as Head of Sana Innovation Research, until March 2024. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, and served as Visiting Scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) from March 2017 to February 2021. From March 2017 to October 2018, Dr. Mulligan served as Portfolio Manager at Icahn Capital LP, an investment management firm, and from May 2013 to December 2016, he served as Founding Partner and Senior Managing Director of Sarissa Capital Management LP, a registered investment advisor. From 1996 to 2013, Dr. Mulligan served as the Mallinckrodt Professor of Genetics at Harvard and Director of the Harvard Gene Therapy Initiative. Prior to that, he served as Professor of Molecular Biology at MIT and a member of the Whitehead Institute for Biomedical Research. Dr. Mulligan currently serves on the boards of directors of Biogen Inc., a public biotechnology company, and Bausch Health Companies Inc., a public pharmaceutical company. Dr. Mulligan’s honors include the MacArthur Foundation Genius Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize. Dr. Mulligan received his Ph.D. in Biochemistry from the Stanford University School of Medicine and his B.S. from MIT.

What is Richard Mulligan's net worth?: The estimated net worth of Richard Mulligan is at least $14.75 million as of September 24th, 2024. Mulligan owns 2,848,121 shares of Sana Biotechnology stock worth more than $14,753,267 as of December 4th. This net worth estimate does not reflect any other assets that Mulligan may own. Learn More about Richard Mulligan's net worth.
How do I contact Richard Mulligan?: The corporate mailing address for Mulligan and other Sana Biotechnology executives is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. Sana Biotechnology can also be reached via phone at 206-701-7914 and via email at [email protected]. Learn More on Richard Mulligan's contact information.
Has Richard Mulligan been buying or selling shares of Sana Biotechnology?: Richard Mulligan has not been actively trading shares of Sana Biotechnology over the course of the past ninety days. Most recently, Richard Mulligan sold 150,000 shares of the business's stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a transaction totalling $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares of the company's stock, valued at $11,620,333.68. Learn More on Richard Mulligan's trading history.
Who are Sana Biotechnology's active insiders?: Sana Biotechnology's insider roster includes Nathan . (Exec. VP & CFO ), Steven Harr (Pres), Christian Hordo (EVP), Richard Mulligan (Director), and Robert Nelsen (Director). Learn More on Sana Biotechnology's active insiders.
Are insiders buying or selling shares of Sana Biotechnology?: During the last year, insiders at the sold shares 1 times. They sold a total of 290,912 shares worth more than $1,888,018.88. The most recent insider tranaction occured on January, 8th when insider Fmr Llc sold 290,912 shares worth more than $1,888,018.88. Insiders at Sana Biotechnology own 30.1% of the company. Learn More about insider trades at Sana Biotechnology.
Information on this page was last updated on 1/8/2025.

Richard Mulligan Insider Trading History at Sana Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/24/2024	Sell	150,000	$4.08	$612,000.00	2,848,121

Richard Mulligan Buying and Selling Activity at Sana Biotechnology

Sana Biotechnology Company Overview

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Today's Range

Now: $5.18

$4.41

$5.49

50 Day Range

MA: $4.36

$3.23

$5.92

2 Week Range

Now: $5.18

$1.26

$7.30

Volume

11,164,615 shs

Average Volume

4,081,570 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95